Peptide Therapy and the FDA: What Patients Need to Know in 2026

If you have been hearing more about peptide therapy lately, there is a good reason. Peptides have become an increasingly common topic in conversations about wellness, practive aging, metabolic health, recovery, and personalized medicine. At the same time, the regulatory landscape surrounding compounded peptides has been changing, leaving many patients wondering what is actually happening and what it means for their treatment options.

An important development took place this summer when the FDA’s Pharmacy Compounding Advisory Committee (PCAC) reviewed several peptides and voted to recommend that six of the seven under consideration be included in Category 1 of the FDA’s Bulk Drug Substances List.

The six peptides receiving the committee’s recommendation were:

• BPC-157
• TB-500
• KPV
• Epithalon
• Semax
• MOTS-c

This is encouraging news for patients and providers who believe there may be a role for individualized peptide therapy. However, there is an important distinction to make: the advisory committee’s recommendation is not the FDA’s final decision.

What Is the FDA Reviewing?

To understand why the recent recommendation matters, it helps to understand the role of compounded medications.

Compounding pharmacies prepare medications for individual patients when a commercially available medication does not meet a particular medical need. Compounding can allow a physician and patient to consider different formulations, strengths or delivery methods when medically appropriate. However, compounded medications are subject to specific regulatory requirements, and not every substance can simply be compounded because a physician believes it may be beneficial.

The FDA maintains a Bulk Drug Substances List that identifies substances that may be used by compounders under certain circumstances. The agency has been evaluating a number of peptides in the context of this regulatory framework.

The PCAC’s role is advisory. Its recommendations provide input to the FDA, but the committee does not make the final regulatory determination.

That means patients should view the recent vote as an important development in an ongoing process, not as a blanket approval of peptide therapy.

What Does the Recent Recommendation Mean for Patients?

The simplest answer is: we are encouraged, but we are still waiting for the FDA’s final decisions.

The committee’s recommendation suggests that the six peptides may ultimately be eligible for inclusion on the Bulk Drug Substances List, assuming the FDA follows the recommendation and completes the necessary regulatory process.

It is important to remember that FDA regulatory status and medical appropriateness are two different questions.

Even if a substance can legally be compounded, that does not automatically mean it is appropriate for every patient, or that there is strong clinical evidence supporting every potential use.

That is where individualized medical care becomes particularly important.

Peptide Therapy Is Not One-Size-Fits-All

At Anti-Aging Northwest, we have never believed that healthcare should follow a one-size-fits-all model.

Every patient has a different medical history, different goals and different factors that need to be considered when developing a treatment plan. A therapy that makes sense for one patient may not make sense for another. That is particularly important when discussing emerging therapies.

Peptides are a broad category of compounds, and they do not all work in the same way or have the same amount of research behind them. Some have been studied extensively in specific medical applications, while others have considerably less clinical evidence supporting the uses for which they are sometimes promoted.

For that reason, peptide therapy should not be approached simply as a wellness trend or something to try because it is popular online. A responsible approach starts with the individual patient.

What are we trying to accomplish? What does the patient’s medical history tell us? What other medications or treatments are being used? What evidence exists for the therapy being considered? What are the potential benefits, limitations and risks?

Those are the conversations that should guide treatment decisions.

Why Quality and Medical Oversight Matter

The growing interest in peptides makes it more important than ever for patients to pay attention to where medications come from.

Compounded medications should be prepared by reputable pharmacies operating within applicable regulatory and quality standards. Patients should also understand exactly what they are receiving, how it is intended to be used and who is overseeing their care. Purchasing products marketed online as “research peptides” or obtaining medications from questionable sources is not the same thing as receiving a prescribed compounded medication through an appropriate medical and pharmacy relationship.

Patients should never assume that something is safe simply because it is labeled a peptide or because someone online reports having a positive experience with it.

Medical supervision matters.

What Happens Next?

The next step is for the FDA to consider the advisory committee’s recommendations and make its final determinations.

Until those decisions are announced, the regulatory landscape remains in transition. That means patients may continue to see conflicting information about which peptides can be compounded, which are being reviewed and what may change in the months ahead. We will continue monitoring those developments closely.

Our goal at Anti-Aging Northwest has never been to chase the newest treatment simply because it is generating attention. We believe in evaluating new therapies thoughtfully, looking at the available evidence and considering whether a treatment has a legitimate place in an individual patient’s care.

Peptide therapy is an area of medicine that continues to evolve. There is legitimate scientific interest in many different peptides, but there are also important questions that remain unanswered for some therapies and applications.

That combination of potential, ongoing research and appropriate caution is exactly why medical guidance is so important.

The Bottom Line on Peptide Therapy

The recent PCAC recommendation is an encouraging development, particularly for patients who may benefit from individualized treatment options. But it is not the final word from the FDA, and it does not mean that all peptides are now approved or appropriate for all uses. For patients, the best approach is to stay informed without getting caught up in the hype.

As the FDA completes its review, we will continue to follow the science and the regulatory process and share meaningful updates with our patients.

At Anti-Aging Northwest, our philosophy remains the same: use the best tools available, when they are appropriate, and always put the individual patient first.

If you have questions about peptide therapy or how the changing regulatory landscape may affect your treatment, talk with your healthcare provider. The right treatment decision should always begin with a conversation about you.